Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 519.47% and ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Sales for breast cancer drug Verzenio jumped 32% year over ...

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... Lilly’s revenue growth is being driven by higher ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

Eli Lilly’s relatively new products should continue to drive the sales growth. The company is expected to post over 2.5x y-o-y rise in Mounjaro sales to around $3.5 billion. Verzenio sales ...

Eli Lilly’s relatively new products should continue to drive the sales growth. The company is expected to post over 2.5x y-o-y rise in Mounjaro sales to around $3.5 billion. Verzenio sales ...

Eli Lilly has a long history of developing drugs to treat a variety of conditions. For example, its third-best-selling drug Verzenio is used to help treat breast cancer, while its sixth-best ...

Threats: Intense competition and patent expirations leading to generic competition.

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...